Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention

Heart

Volumn 98, Issue 18, 2012, Pages 1359-1365

  Marshall, Andrew ^a,b   Cheetham, Andrew ^a   George, Robert S ^a   Mason, Mark ^a   Kelion, Andrew D ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b WATFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; TETROFOSMIN TC 99M;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ARRHYTHMIAS, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS IMPLANTATION; RADIOPHARMACEUTICALS; ROC CURVE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84865168932     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302321     Document Type: Article

References (27)

1. Kannel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death in the Framingham Study. Am Heart J 1988;115:869-75. (Pubitemid 18093155)
2. Anon. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997;337:1576-83.
3. Connolly SJ, Gent M, Roberts RS, et al . Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302. (Pubitemid 30158618)
4. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54. (Pubitemid 30648765)
5. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. (Pubitemid 34984635)
6. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
7. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. (Pubitemid 40110811)
8. Lyman S, Sedrakyan A, Do H, et al. Infrequent physician use of implantable cardioverter-defibrillators risks patient safety. Heart 2011; 97:1655-60.
9. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.
10. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
11. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
12. Agostini D, Verberne HJ, Hamon M, et al. Cardiac 123I-MIBG scintigraphy in heart failure. Q J Nucl Med Mol Imaging 2008;52:369-77.
13. Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001; 86:656-60. (Pubitemid 33086883)
14. Verberne HJ, Brewster LM, Somsen GA, et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29:1147-59. (Pubitemid 351844881)
15. Kasama S, Toyama T, Sumino H, et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011;97:20-6.
16. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, et al. Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Heart 2011;97:1828-33.
17. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-346. (Pubitemid 44382683)
18. National Institute for Health and Clinical Excellence. Implantable Cardioverter Defibrillators for Arrhythmias (TA095). 2006. http://www.nice.org. uk/TA095 (accessed 25 Apr 2012).
19. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40. (Pubitemid 26428217)
20. Daubert JP, Zareba W, Cannom DS, et al . Inappropriate implantable cardioverterdefibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51:1357-65. (Pubitemid 351443082)
21. Liew R. Prediction of sudden arrhythmic death following acute myocardial infarction. Heart 2010;96 :1086-94.
22. Gupta A, Hoang DD, Karliner L, et al. Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: a meta-analysis. Am Heart J 2012;163:354-64.
23. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31. (Pubitemid 36503797)
24. Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33. (Pubitemid 351225660)
25. Nishisato K, Hashimoto A, Nakata T, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med 2010;51:1241-9.
26. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-77.
27. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 metaiodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart1 Failure) study. J Am Coll Cardiol 2010;55:2212-21.